Table 3.
Medical conditions or other indications for administration of PCV13,* and indications for PPSV23† administration and revaccination for children aged 6–18 years§ (From Centers for Disease Control and Prevention (CDC). Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013; 62: 521–524)
| Risk group | Underlying medical condition | PCV13 | PPSV23 | |
|---|---|---|---|---|
| Recommended | Recommended | Revaccination 5 yrs | ||
| Immunocompetent Persons |
Chronic heart disease¶ | ✓ | ||
| Chronic lung disease** | ✓ | |||
| Diabetes mellitus | ✓ | |||
| Cerebrospinal fluid leaks | ✓ | ✓ | ||
| Cochlear implants | ✓ | ✓ | ||
| Alcoholism | ✓ | |||
| Chronic liver disease | ✓ | |||
| Cigarette smoking | ✓ | |||
| Persons with functional or anatomic asplenia |
Sickle cell disease/other hemaglobinopathies |
✓ | ✓ | ✓ |
| Congenital or acquired asplenia | ✓ | ✓ | ✓ | |
| Immunocompromised persons |
Congenital or acquired immunodeficiencies†† |
✓ | ✓ | ✓ |
| Human immunodeficiency virus infection |
✓ | ✓ | ✓ | |
| Chronic renal failure | ✓ | ✓ | ✓ | |
| Nephrotic syndrome | ✓ | ✓ | ✓ | |
| Leukemia | ✓ | ✓ | ✓ | |
| Lymphoma | ✓ | ✓ | ✓ | |
| Hodgkin disease | ✓ | ✓ | ✓ | |
| Generalized malignancy | ✓ | ✓ | ✓ | |
| Iatrogenic immunosuppression§§ |
✓ | ✓ | ✓ | |
| Solid organ transplant | ✓ | ✓ | ✓ | |
| Multifile myeloma | ✓ | ✓ | ✓ | |
(*13-valent pneumococcal conjugate vaccine.
23-valent pneumococcal polysaccharide vaccine.
Children aged 2–5 years with chronic conditions (e.g., heart disease or diabetes), immunocompromising conditions (e.g., human immunodeficiency virus), functional or anatomic asplenia (including sickle cell disease), cerebrospinal fluid leaks, or cochlear implants, and who have not previously received PCV13, have been recommended to receive PCV13 since 2010.
Including congestive heart failure and cardiomyopathies.
Including chronic obstructive pulmonary disease, emphysema, and asthma.
Includes B-(humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).
Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.)